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Abstract
Background: Children with vernal keratoconjunctivitis (VKC) present
symptoms that are similar to other ocular allergies, but more pronounced,
and are controlled using topical steroids. To avoid excessive and prolonged use
of topical steroid eye drops, over the past 20 years galenic eye drops of
cyclosporine with a concentration of 1% to 2% and tacrolimus with a
concentration of 0.1% have been introduced as a treatment for the severe and
unresponsive forms. The main symptoms of VKC occur most frequently during
the spring and tend to get worse during the summer, meaning that affected
children tend to avoid exposure to sunlight. The aim of this study was to assess
the most common cell types present in the conjunctiva of children with VKC,
how ocular treatment can influence them, and whether affected children
express a typical conjunctival pattern, which could be useful as a pathogno-
monic pattern of VKC, allowing us to study this rare eye disease.
Method: This was a cohort study of 56 children, of whom 17 were not receiving
any treatment at the time of testing, 14 were using steroid eye drops or had
taken them in the previous 10 days, and 25 were treated with cyclosporine eye
drops or tacrolimus eye drops 0.1%.
Result: Children in group 1 (no topical therapy) express more epithelial cells,
neutrophils, mast cells, eosinophils, and lymphocytes than the other two groups.
Conclusion: Given the ease of performance, when conducting further
longitudinal studies, the conjunctival cytology examination could be used, on
the one hand, to diagnose VKC, especially when the clinical diagnosis is
uncertain, and, on the other, to follow disease evolution and monitor the
response to topical treatment.
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1 | INTRODUCTION
Vernal keratoconjunctivitis (VKC) is a chronic, bilateral,
and asymmetric form of keratoconjunctivitis that
primarily affects boys in the first decade of life.1,2 The
prevalence of VKC varies greatly and increases with
vicinity to the equator. In Scandinavian countries,
prevalence is close to 0%, whereas it reaches 0.27% in
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Italy3 and is higher still in Africa, with a reported
prevalence of 6% in Ethiopia.4 Although the causes of
VKC are still unclear, there is a strong correlation with
exposure to sunlight, which exacerbates the disease.5
VKC is characterized by itch, photophobia, white
mucous discharge, lacrimation, and foreign body sensa-
tions.6 There are three forms of VKC tarsal, limbal, and
mixed. The tarsal form is characterized by the presence of
papillae in the upper tarsal lid, and the limbal form by
gelatinous infiltrate in the limbus and Horner‐Trantas
dots.4
Although VKC usually resolves after puberty, it can
lead to severe visual impairments if it is not adequately
treated. Sight loss is reported in 5% to 30% of cases due to
complications such as shield ulcers, corneal neovascular-
ization, and keratoconus, and prolonged use of steroid
therapy can cause cataracts and glaucoma.7
Normal conjunctival cytology is characterized by (a)
epithelial cells, which are round or columnar; (b)
sporadic neutrophils or lymphocytes; (c) absence of
eosinophils and mast cells. In the event of inflammation,
immune system cells reach the damage site through the
vessels, disperse by diapedesis and gradually proliferate.
Analyzing conjunctival scrapings can direct diagnosis
towards an eye infection (eg, the presence of monocytes
and/or macrophages indicates the possible presence of
chlamydia, whereas lymphocytes may suggest a viral
infection), tear film abnormalities (keratinized cells), or
ocular allergy (eosinophils and mast cells). In VKC,
conjunctival scrapings are characterized by the presence
of eosinophils and mast cells, as in other ocular allergies,
and few neutrophils.8
Small, intensely colored eosinophils have recently
migrated to the inflammation site, whereas larger, less
brightly colored eosinophils indicate degranulation.9,10
The higher the number of inflammatory cells, the worse
the ocular symptoms.11 Although the presence of
eosinophils confirms the presence of an ocular allergy
or VKC, their absence cannot exclude them.12
2 | MATERIALS AND METHODS
This was an observational study on 56 children attending
Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico di Milano for active VKC between June and
September 2017. All of these patients were screened by
conjunctival cytology. Diagnosis of VKC was performed
by a pediatric ophthalmologist and the children were
classified using the Bonini grading system.6
Each child was tested for (a) total serum immunoglo-
bulin E (IgE); (b) presence of specific IgE for common
allergens (birch, hazel, olive tree, grass, pellitory,
ragweed, wormwood, Dermatophagoides farinae, Derma-
tophagoides pteronyssinus, Alternaria, cat and dog’s
dander), with a positive result >0.10 KUA/L; and (c)
prick test for common inhalant allergens (birch, hazel,
olive tree, grass, pellitory, ragweed, wormwood, D.
farinae, D. pteronyssinus, Alternaria, cat and dog’s
dander).
The study was approved by the local Institutional
Ethics Committee (Comitato Etico Milano Area 2) and
was conducted in compliance with the ethical principles
of the Declaration of Helsinki (no 312_2019). All the
patients’ legal guardians gave their informed consent.
There were three treatment groups:
1) Group 1: 17 children who were not using immuno-
modulatory therapy or who had not used steroids for
at least 10 days;
2) Group 2: 14 children treated with steroid eye drops;
3) Group 3: 25 children treated with cyclosporine 1% or
tacrolimus 0.1% eye drops.
The following data were recorded for each patient:
age, gender, atopy, inhalant‐specific IgE levels, or positive
skin prick test.
Ocular cytology consists of (a) sampling; (b) fixation
and staining; (c) microscopic exam. For sampling, we
used a nasal curette (Rhino‐Probe). Sampling was
performed on the posterior surface of the upper eyelid.
We decided to sample the upper eyelid conjunctiva,
rather than the lower eyelid, because the presence of
papillae in this latter site is extremely rare, whereas they
are almost always present on the upper lid.13 The
curette was then scraped over a slide, that was fixed and
stained with May‐Grunwald‐Giemsa and examined
using an optical microscope. Each sample slide was
examined for the presence of epithelial cells, eosino-
phils, neutrophils, mast cells, lymphocytes, bacteria,
and fungi.
Each parameter was scored from 0 to 4, according to
the Gelardi scoring system14
0: absence
½+ : occasional
1 + : few scattered cells, small clumps
2 + : moderate number, large clumps
3 + : large clumps not covering the field
4 + : clumps covering the entire field.
The results are presented as medians, quartiles (Q1
and Q3), and ranges. The differences between the groups
were initially investigated with univariate analyses using
Wilcoxon rank tests for differences in median values and
χ2 and Fischer exact tests for differences in frequency.
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3 | RESULTS
The age range was 5 to 15 years, with a median age of 9.4
years. Of the total, 71.4% of children were male, 78.1%
had a mixed form of VKC, 18.1% a tarsal form, and 3.6% a
limbal form. No patient had corneal involvement (shield
ulcers or punctate keratitis) during the sampling period.
According to the Bonini grading system, 14.5% of
children had mild‐intermittent VKC (grade 1, occasional
use of antiallergy eye drops), 14.5% moderate, intermit-
tent or persistent VKC (grade 2, daily use of antiallergy
eye drops), 52.7% severe VKC (grade 3, not only daily use
of antiallergy eye drops, but also of cyclosporine eye
drops and topical pulsed steroids), 18.1% very severe VKC
(grade 4, daily use of antiallergy eye drops, cyclosporine
eye drops and topical high‐dose pulsed steroid eye drops
to control the disease).6
Children in group 1 made only occasional use of
antihistamine eye drops, mast cell stabilizers or dual‐
acting agents. The most frequent product used in this
group was ketotifen ophthalmic eye drops (90%).
Children in group 2 were using steroid eye drops at
the time of sampling (dexamethasone sodium phosphate
0.15% eye drops in all cases).
Children in group 3 were using cyclosporine 1% eye
drops two to three times a day (60%, 15 patients) or
tacrolimus 0.1% eye drops twice a day (40%, 10 patients).
Seventy‐one percent had a parent with allergic rhinitis
or asthma; 53% had positive prick tests for at least one
allergen amongst birch, hazel, olive trees, grass, pellitory,
ragweed, wormwood, D. farinae, D. pteronyssinus, Alter-
naria, and cat and dog dander, whereas 60% had specific
IgE positivity for at least one of these allergens.
No significant differences were observed between the
three treatment groups in terms of age, gender, positive
family history of allergy, positive prick test, or specific IgE.
Conjunctival brushing cytology was performed for
epithelial cells, neutrophils, eosinophils, and eosinophil
degranulation, mast cells and mast cell degranulation,
and lymphocytes. Each parameter was allocated a score
of between 0 (absence) and 3 (strong presence).
Epithelial cells were more prevalent in group 1 (no
topical therapy) than groups 2 and 3, with mean values of
3 (2‐3) in group 1, 2 (1‐2) in group 2, and 2 (1.5‐3) in
group 3 (P values .0014 between groups 1 and 2, and .03
between groups 1 and 3).
Neutrophils were more prevalent in groups 1 and 3
than in group 2 (steroid therapy on‐going or used in the
previous 10 days), with mean values of 1 (1‐1) in group 1, 1
(0.3‐1) in group 3, and 0.3 (0‐0.5) in group 2 (P values .0019
between groups 1 and 2, and .03 between groups 2 and 3).
Mast cells were more prevalent in group 1 than in
groups 2 and 3, with mean values of 1 (1‐2), 1 (0‐1), and
1 (0.8‐2), respectively (P values .01 between groups 1 and
2, and .045 between groups 1 and 3).
There was no statistically significant difference in
terms of mast cell degranulation in the three groups, with
a mean score of 1 in all groups (P values .16 between
groups 1 and 2, .43 between groups 2 and 3, and .45
between groups 1 and 3).
Eosinophils were less prevalent in the children in group
2 (0.3 [0‐1]) (steroid therapy on‐going or in the previous 10
days) and group 3 (0.5 [0‐1]) (cyclosporine or tacrolimus eye
drops) than in group 1 (1 [0.5‐2]), with a statistically
significant difference between groups 1 and 3 (P value .018).
As for mast cell degranulation, eosinophil degranula-
tion did not show any statically significant difference
between the groups, with scores of 0 (0‐0) in all three.
Lymphocytes were more prevalent in group 1, but
without any statistically significant difference between
the three groups (mean values of 1 [0‐1], 0 [0‐1], and 0 [0‐
1] for groups 1, 2, and 3, respectively. P values .28
between groups 1 and 2, .10 between groups 1 and 3, .67
between groups 2 and 3).
We also calculated a “worse eye score,” that is, based
on the neutrophil, mast cell, eosinophil, and lymphocyte
count. The mean score was 4.5 (2.8‐5.3), 2.8 (0.5‐3.5), and
3.0 (1.8‐4.0) for groups 1, 2, and 3, respectively, with P
values of .0015 between groups 1 and 2 and .03 between
groups 1 and 3 (Table 1).
None of the analyzed conjunctival scrapings showed
the presence of bacteria or fungi.
4 | DISCUSSION
The normal cytological situation consists of conjunctival
epithelial cells without cytoplasm or nuclear abnormal-
ities. Epithelial cells have a roundish or columnar shape;
flat cells originate from the conjunctiva. Inflammatory
immune system cells are not usually found, except for a
few sporadic neutrophils and lymphocytes. Eosinophils
and mast cells are, therefore, absent both in the
epithelium and in the tunica propria of the healthy
conjunctiva, so the finding of these cells suggests a
pathological process. In the presence of inflammation, a
significant increase in inflammatory cells is caused by
diapedesis from the conjunctival capillaries, with diverse
and often characteristic representations of the various
elements depending on the causes that gave rise to the
pathological process. The number of inflammatory
immune elements always correlates with the severity of
the symptoms and the underlying conjunctival condition.
The diagnostic suspicion changed according to the
prevailing cell type. Thus, whereas neutrophils are an
indicator of infectious disease, such as bacterial or viral
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conjunctivitis, or an allergic or irritative condition, such
as giant papillary conjunctivitis, lymphocytes are typical
of adenoviral conjunctivitis, Herpes simplex virus (HSV),
or drugs. Monocytes are frequently observed in con-
junctivitis caused by Chlamydia or HSV, whereas
macrophages and plasma cells are found in the presence
of in chlamydial conjunctivitis. The presence of eosino-
phils and mast cells suggest allergic conjunctivitis or
VKC.11,15
Furthermore, the abundant presence of Th2 cytokines
(interleukin‐4 [IL‐4] and IL‐5) and their receptors in tears
and in the serum of VKC patients confirm the crucial role
played by Th2‐type immune response in the onset and
progression of the inflammation observed in VKC.16-18
IL‐2, interferon‐gamma, and tumor necrosis factor‐
beta, cytokines secreted by Th1 cells, on the other hand,
are not increased in VKC.19
Our study once again highlights that eosinophils could
be used as a marker for ocular allergy.15 Indeed, in our
cohort of children with VKC, like those published by
Fanelli et al11 and Spadavecchia et al,20 ocular cytology
shows an increase in eosinophils in the conjunctiva,
whereas they are absent in healthy subjects. Moreover,
our study clearly shows that appropriate topical therapy
with steroid eye drops (children in group 2) or
cyclosporine/tacrolimus eye drops underwent a statisti-
cally significant reduction in this cell type. Therefore,
given the ease of performance, when conducting further
longitudinal studies, conjunctival scraping and eosino-
phil tests could be used, on the one hand, to diagnose
VKC (or other ocular allergies), especially when diag-
nosis is uncertain because it is based on clinical signs and
symptoms alone, and, on the other hand, to follow the
disease’s evolution and monitor the efficacy of the ocular
treatment.
As for eosinophils, children with VKC show an
elevated presence of mast cells in the conjunctiva,
especially those who are not receiving any eye treatment.
When adequately treated, with either steroid eye drops
(group 2) or cyclosporine or tacrolimus eye drops (group
3), this high concentration of mast cells showed a
considerable decrease.
Our study did not reveal a statistically significant
difference in terms of eosinophils and mast cell
degranulation in the three groups studied.
Neutrophils were also far more prevalent in group 1
(no therapy children) than in the other groups (a fact that
is particularly evident when group 1 [no therapy] is
compared with group 2 [steroid eye drops], with a P value
of .0019), which once again shows that immune‐
mediated inflammation in VKC is a complex phenom-
enon that does not merely involve eosinophils and mast
cells (ie, “allergic” cells), but also other immune system
components. This could be why children with VKC show
limited and partial response to antihistamine therapy
alone, consisting in a reduction in reported itch only.
The presence of lymphocytes was higher than
reported in previous studies on healthy subjects but
without any statically significant differences between the
three groups.
TABLE 1 Population characteristics
Total
(N= 56)
Group 1
(n= 17)
Group 2
(n= 14)
Group 3
(n= 25)
P value
(1 vs 2)
P value
(1 vs 3)
P value
(2 vs 3)
Male 40 (71.4) 12 (70.6) 10 (71.4) 18 (72) 1.0 1.0 1.0
Age, y 9.4 (7.8‐11.8) 8.5 (7.7‐11.5) 8.6 (6.7‐11.1) 10.6 (8.5‐13.3) .61 .09 .042
Family history of atopy 39/55 (70.9) 12/16 (75) 11 (78.6) 16 (64) 1.0 .51 .48
Serum IgE 196 (49‐547) 144 (38‐461) 166 (35‐479) 318 (118‐736) .98 .13 .26
IgE >50 UI/mL 40/53 11/16 (68.8) 8/12 (66.7) 21 (84) 1.0 .44 .39
Positive prick test 29/55 9 (52.9) 6/13 (46.2) 14 (56) 1.0 1.0 .73
Positive RAST test 33/53 9/16 (56.3) 7/12 (58.3) 17 (68) 1.0 .52 .72
Worse eye
Epithelial cells 2 (2‐3) 3 (2‐3) 2 (1‐2) 2 (1.5‐3) .0014 .03 .16
Neutrophils 1 (0‐1) 1 (1‐1) 0.3 (0‐0.5) 1 (0.3‐1) .0019 .19 .03
Mast cells 1 (0.6‐1) 1 (1‐2) 1 (0‐1) 1 (0.8‐2) .01 .60 .045
Mast cell degranulation 1 (0‐2) 1 (0.5‐2) 1 (0‐1) 1 (0‐1.5) .16 .43 .45
Eosinophils 0.5 (0‐1) 1 (0.5‐2) 0.3 (0‐1) 0.5 (0‐1) .055 .018 .98
Eosinophil degranulation 0 (0‐0) 0 (0‐0) 0 (0‐0) 0 (0‐0) .70 .60 .39
Lymphocytes 0 (0‐1) 1 (0‐1) 0 (0‐1) 0 (0‐1) .28 .10 .67
Worse eye score 3.3 (1.5‐4.4) 4.5 (2.8‐5.3) 2.8 (0.5‐3.5) 3.0 (1.8‐4.0) .0015 .03 .26
Note: Main findings at conjunctival scraping of the analyzed groups.
Abbreviation: IgE, Immunoglobulin E.
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In our study, the evaluation of the “worse eye score”
showed that appropriate ocular treatment is able to
reduce the conjunctival cellularity of children with VKC,
with both topical steroid therapy and cyclosporine or
tacrolimus eye drops.
The presence or absence of prick test positivity, serum
IgE elevation or common antigen‐specific IgE positivity
did not influence the cellularity of ocular specimens,
neither did a positive familiar history of rhinitis and
asthma.
5 | CONCLUSIONS
Like children with seasonal or perennial ocular allergies,
those with VKC, present eosinophils and mast cells in the
upper tarsal conjunctiva.
Children in group 1 (no topical therapy) express more
epithelial cells, neutrophils, mast cells, eosinophils, and
lymphocytes than the other two groups, showing that eye
treatment can influence the composition of the con-
junctiva in affected children.
Thus, given the ease of performance, when conducting
further longitudinal studies, the conjunctival cytology
examination and eosinophil test could be used, on the
one hand, to diagnose VKC, especially when the clinical
diagnosis is uncertain and, on the other hand, to follow
disease evolution and monitor the response to topical
treatment.
Confirmation of these results with large‐scale studies
could not only lead to the development of personalized
therapies but also provide greater insight into the
pathogenesis of VKC.
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